1. Home
  2. XAIR vs SILO Comparison

XAIR vs SILO Comparison

Compare XAIR & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

N/A

Current Price

$2.07

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

N/A

Current Price

$1.77

Market Cap

3.1M

ML Signal

N/A

Company Overview

Basic Information
Metric
XAIR
SILO
Founded
2011
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
3.1M
IPO Year
2015
2011

Fundamental Metrics

Financial Performance
Metric
XAIR
SILO
Price
$2.07
$1.77
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $20.00
N/A
AVG Volume (30 Days)
★ 50.6K
35.1K
Earning Date
11-11-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.98
EPS
N/A
★ N/A
Revenue
★ $7,679,000.00
$72,102.00
Revenue This Year
$6.52
N/A
Revenue Next Year
$104.36
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 107.26
N/A
52 Week Low
$0.33
$1.10
52 Week High
$8.19
$10.43

Technical Indicators

Market Signals
Indicator
XAIR
SILO
Relative Strength Index (RSI) 40.75 65.70
Support Level $2.05 $1.18
Resistance Level $2.49 $4.80
Average True Range (ATR) 0.29 0.16
MACD 0.04 0.10
Stochastic Oscillator 13.74 81.34

Price Performance

Historical Comparison
XAIR
SILO

About XAIR Beyond Air Inc.

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Share on Social Networks: